Skip to main content

Industry News

  • U.S. health regulators declined to approve a fixed-dose diabetes drug combination from AstraZeneca, delaying its launch and dealing a blow to an important plank of the drugmaker's business. Food and Drug Administration (FDA) stating that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin.

  • U.S. health regulators approved Praxbind, a reversal agent made by Germany Private held Boehringer Ingelheim, for use in emergency situations by patients taking the company's widely used Pradaxa blood thinner. Praxbind, an intravenous injection, is the first reversal agent approved specifically for Pradaxa and works by binding to the drug compound to neutralize it.

  • Sandoz Canada launch a brand new multi-platform application, which allows healthcare professionals to have this crucial information at their fingertips. Sandoz Pro app (sandozpro.sandoz.ca) allows users to view information on availability of injectable medicines. This new tool is designed for healthcare professionals and buyers who want to make the most of their time, as it helps them plan their injectable drug supplies and make informed decisions at all times.

  • Merck, a leading science and technology company relaunch its brand identity. It will introduce  new logo reflect the transformation into a global science and technology company. Outside the United States and Canada, the company will operate uniformly as Merck.

  • Roche Pharma India recently introduce  two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer.

Subscribe to Industry News